掌桥专利:专业的专利平台
掌桥专利
首页

一种重组双功能融合蛋白及应用

文献发布时间:2023-06-19 10:36:57


一种重组双功能融合蛋白及应用

技术领域

本发明属于融合蛋白技术领域,具体涉及一种重组双功能融合蛋白及应用。

背景技术

间皮素(mesotnelin,MSLN)是一种40kDa的细胞表面糖蛋白,不是癌症特异性抗原,是一种分化抗原,在正常组织中以相对较低的水平表达。与正常组织相比,间皮素在多种类型的实体瘤中高表达,例如胰腺癌、卵巢癌、恶性间皮瘤、肺腺癌以及子宫内膜癌、胆道胃癌和前列腺癌。间皮素在胸膜、心包和腹膜内衬的正常间皮细胞上表达。间皮素在正常组织上的有限分布使其成为肿瘤特异性治疗的有望靶标。间皮素基因编码一个71kDa的前体蛋白,由2138bp长的cDNA编码,包含628个氨基酸,该蛋白被加工成一个40kDa的膜结合蛋白(称为间皮素)和一个31kDa的脱落片段,称为巨核细胞增强因子(megakaryocyte-potentiating factor,MPF),该片段从细胞中释放出来。间皮素蛋白是单克隆抗体K1识别的抗原,通常是与膜结合的糖脂酰肌醇(GPI)连接的蛋白质;而MPF是从人胰腺癌细胞系的培养基中分离得到的。间皮素在约30%的癌症中过表达,肿瘤间皮素的表达通常与肿瘤侵袭性增加和临床不良预后有关。

信号调节蛋白(SIRP)是一种穿模糖蛋白,属于跨膜蛋白家族。信号调节蛋白具有三个成员:SIRPα(CD172a)、SIRPβ(CD172b)、SIRPγ(CD172g)。这三个成员具有相似的胞外区域,但胞内结构域不同。胞外结构域包含三个免疫球蛋白(Ig)样区域,其中第一个Ig样区域为N端V样结构域(D1),第二、三个区域是两个C1样结构域。SIRPα(CD172a)的胞内结构域包含两个抑制性信号传导区域默契可以抑制信号转导以及相应的细胞功能。SIRP主要表达在巨噬细胞(M)、树突状细胞(DC)和神经元中。

CD47也是一种穿模糖蛋白,属于免疫球蛋白超家族,且在包括红细胞在内的所有细胞类型的表面表达,在细胞与细胞之间的通讯中具有多种功能。CD47与多种配体相互作用,例如整联蛋白、SIRPα、SIRPγ和血小板反应蛋白。CD47与SIRPα相互作用,CD47下调表达SIRPα的吞噬细胞的活性。研究发现,除正常组织表达CD47外,许多肿瘤细胞过度表达CD47,并以这种方式,传递“不要吃我”信号,从而避免被机体免疫监视发现而被先天免疫细胞杀死(免疫逃逸)。CD47抑制树突状细胞(DC)的成熟和激活。CD47还涉及细胞凋亡、存活、增殖、粘附、迁移和调节血管生成、血压、组织灌注或血小板稳态等过程。在癌症例如白血病、淋巴瘤、乳腺癌、结肠癌、卵巢癌、膀胱癌、前列腺癌和神经胶质瘤中,高水平的CD47与不良临床结果有关。迄今没有对于任何同时靶向MSLN和CD47的双特异性抗体。

发明内容

有鉴于此,本发明的目的在于提供一种重组双功能融合蛋白及应用,所述融合蛋白同时与MSLN以及CD47结合,从而发挥对MSLN阳性肿瘤细胞的治疗作用,并且阻断CD47与巨噬细胞表面上的SIRP结合,刺激巨噬细胞对肿瘤细胞的吞噬作用,具有显著的抗肿瘤活性。

为了实现上述发明目的,本发明提供以下技术方案:

本发明提供了一种重组双功能融合蛋白,所述融合蛋白由抗人MSLN抗体与结合人CD47蛋白的单域结构连接而成,所述重组双功能融合蛋白包括第一结合结构域和第二结合结构域;

所述第一结合结构域特异性结合靶分子人MSLN蛋白;所述第二结合结构域特异性结合靶分子CD47蛋白。

优选的,所述结合人CD47蛋白的单域结构包括衍生自人信号调节蛋白膜外N端V样结构域(D1)。

优选的,所述衍生自人信号调节蛋白膜外N端V样结构域(D1)的氨基酸序列如SEQID NO.1所示。

优选的,所述结合人CD47蛋白的单域结构还包括与SEQ ID NO.1所示序列具有至少80%、85%、90%、95%、98%或99%相似性的氨基酸。

优选的,所述融合蛋白包括重链和轻链,所述重链包括多肽链VH

优选的,所述肽链VH

优选的,所述融合蛋白包括重链和轻链,所述重链包括多肽链VH

优选的,所述多肽链VH

优选的,所述融合蛋白包括重链和轻链,所述重链包括多肽链V

优选的,所述肽链V

优选的,所述Fc的结构域来源包括野生型或突变型;连接子X为由多个相同或不同氨基酸组成的多肽链。

本发明还提供了一种治疗MSLN阳性肿瘤的药物,所述药物的有效成分包括上述融合蛋白。

本发明提供了一种重组双功能融合蛋白(MSLNmAb-V

附图说明

图1为融合蛋白结构的示意图;图1中A为MSLN抗原;B为CD47抗原;

图2为DOT检测蛋白表达;

图3靶点结合活性测定,其中图3A为靶点结合活性(MSLN),图3B为靶点结合活性(human CD47);

图4为HY202-1、HY202-2、HY202-3对ADCC效应细胞激活活性的影响,其中图4A为NCIH226报告基因测定,图4B为OVCAR-3报告基因测定;

图5为HY202-1、HY202-2、HY202-3对巨噬细胞吞噬活性的影响;

图6为HY202-1、HY202-2、HY202-3的体内抗肿瘤活性。

具体实施方式

本发明提供了一种重组双功能融合蛋白(MSLNmAb-SIRPα),所述融合蛋白由抗人MSLN抗体与结合人CD47蛋白的单域结构连接而成,所述重组双功能融合蛋白包括第一结合结构域和第二结合结构域;

所述第一结合结构域特异性结合靶分子人MSLN蛋白;所述第二结合结构域特异性结合靶分子CD47蛋白。

本发明所述结合人CD47蛋白的单域结构优选包括人信号调节蛋白(SIRPα)膜外N端V样结构域(D1),且所述人信号调节蛋白膜外N端V样结构域(D1)的氨基酸序列优选如SEQID NO.1所示。在本发明中,所述结合人CD47蛋白的单域结构优选还包括与SEQ ID NO.1所示序列具有至少80%、85%、90%、95%、98%或99%相似性的氨基酸。

本发明所述融化蛋白有三种不同的结构,具体结构示意图如图1所示,第一种结构的融合蛋白包括多肽链VH

本发明所述肽链VH

本发明所述Fc的结构域来源优选包括野生型或突变型,更优选为野生型,在本发明实施例中,采用的野生型Fc的氨基酸序列优选如SEQ ID NO.8所示。本发明所述连接子X优选为由多个相同或不同氨基酸组成的多肽链,在本发明实施例中所述连接单元X的氨基酸序列优选如SEQ ID NO.9所示。

本发明所述重组双功能融合蛋白中,人MSLN抗体可杀伤MSLN阳性表达的肿瘤细胞,SIRPα可激活巨噬细胞吞噬CD47阳性表达的肿瘤细胞,将两者结合后,获得上述三种不同的结构,可通过MSLN与CD47两种信号途径杀伤肿瘤细胞。

本发明对所述融合蛋白的制备方法并没有特殊限定,优选的包括人工合成编码各融合蛋白的多肽链的核苷酸序列,并分别克隆至载体,从而分别构建得到HY202-1、HY202-2和HY202-3表达载体;利用所述表达载体电转CHO-K1细胞,诱导蛋白表达并纯化。本发明对所述电转、诱导蛋白表达和纯化的方法并没有特殊限定,利用本领域的常规技术手段即可。

本发明还提供了上述融合蛋白在制备治疗MSLN阳性肿瘤的药物中的应用。本发明所述融合蛋白能够同时与MSLN以及CD47结合,从而通过抗体依赖、细胞介导的细胞毒及补体依赖的细胞毒活性而发挥对MSLN阳性肿瘤细胞的治疗作用,并且阻断CD47与巨噬细胞表面上的SIRP结合,刺激巨噬细胞对肿瘤细胞的吞噬作用,具有显著的抗肿瘤活性;并且其肿瘤抑制效果优于单一抗MSLN单抗治疗;可以用来治疗抗MSLN单抗无效或耐受的肿瘤患者。

本发明还提供了一种治疗MSLN阳性肿瘤的药物,所述药物的有效成分包括上述融合蛋白。

下面结合实施例对本发明提供的一种重组双功能融合蛋白及应用进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。

实施例1

1、表达载体构建

抗体重链采用Amatuximab单抗VH

将抗人MSLN抗体重链VH

将V

2、蛋白表达及纯化

预先准备CHO细胞培养基(CD CHO Medium+8mM GlutaMAX;Gibco,10743-029;Gibco,35050-061)于T75方瓶,37℃预热;准备处于对数生长期的CHO-K1细胞,1×10

3、蛋白表达检测

用DOT blot检测蛋白表达。具体步骤是:根据工作量选择合适大小的硝酸纤维素膜(BBI Life Sciences,F619511-0005),标记每孔对应的位置和方向;取细胞上清原液,96孔膜每孔点样2μL,带标准品(0.01mg/mL,0.1mg/mL,1mg/mL,10mg/mL),晾干;将膜浸没在封闭液(2.5g脱脂奶粉+50mL PBS)中,置于摇床1h,转速60~90rpm;取一支羊抗人IgG-HRP抗体(Jakson Immuno Research,109-035-098)加入到50mL封闭液中,置于摇床1h,转速60~90rpm;用PBS洗膜3~5次,除去脱脂奶粉,置于摇床,转速60~90rpm,每次10min;每张96孔板大小的NC膜用1mL ECL化学发光液(Thermo,34577);使用化学发光成像仪拍照,曝光时间设定为自动曝光,用图像软件对图片进行灰度分析。结果如图2所示,以标准品为基准,单抗与双抗产品均表达,且产量近1g/L。

4、稳定细胞株筛选

基因转染的细胞,电转后24~48h,即用加压培养基对细胞进行稀释,加入到96孔细胞培养板中,每孔含有10000个细胞;细胞融合度达60%,取上清进行DOT检测;选择表达量高的逐步进行扩大培养,检测HPLC-titer,以及相关质量参数分析,最终选择3~5个高表达克隆。经筛选后,选择对数生长期的细胞经有限稀释法进行进一步筛选,将具有最高表达水平的细胞株挑选出来冻存备用。

5、蛋白生产及纯化

将稳定表达细胞株(3×10

6、靶点结合活性

用Elisa法检测靶点结合活性:

分析MSLN的靶点结合活性,具体步骤是:将人MSLN抗原溶解至包被缓冲液中,稀释至0.5μg/mL;然后加入到96孔ELISA检测板中,每孔100μL,然后将ELISA板放置于4℃度冰箱过夜。检测时,用洗涤液(TBS,0.05%Tween-20,pH 7.4)洗涤3次;用封闭液(洗涤液,2%BSA)先37℃封闭1.5h,经洗涤液洗涤3次;然后加入经过稀释的实验组抗体(设置Amatuximab单抗作阳性对照,IgG1阴性对照),37℃孵育1h,经洗涤液洗涤3次;然后加入辣根过氧化物酶(HRP)标记的、针对人IgG Fc片段的山羊抗体(Jakson Immuno Research,109-035-098),室温孵育1h;洗涤6次后加入HRP的底物,避光显色反应10~15min后加入终止液(1M H

表1靶点结合活性

用流式细胞术检测分析CD47的靶点结合活性,具体步骤是:取10

表2靶点结合活性

7、抗体依赖性细胞毒性

将对数生长期的10

Response(Relative luminescence units)=(处理样品数值-背景值)/(无抗体对照组-背景值);

利用GraphPad绘制曲线:纵坐标为光信号值,横坐标为药物浓度的对数值;据此可计算该抗体效应的EC50数值。结果如表3~4和图4所示,人肺鳞癌细胞NCIH226及乳腺癌细胞OVCAR-3中,双抗产品均明显激活ADCC功能,且效果优于单抗产品。

表3 NCIH226细胞报告基因测定

表4 OVCAR3报告基因测定

8、抗体依赖性细胞吞噬

将小鼠巨噬细胞(Raw264.7)加入到96孔细胞培养板中,每孔5×10

9、体内抗肿瘤药效实验

利用NCIH226细胞皮下肿瘤模型,对MSLNmAb-SIRPα的体内抗肿瘤活性进行研究。给30只裸鼠尾皮下注射NCIH226细胞,每只小鼠注射3×10

以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。

序列表

<110> 南京华岩生物技术有限公司

河北神宇生物技术有限公司

<120> 一种重组双功能融合蛋白及应用

<141> 2020-11-30

<160> 16

<170> SIPOSequenceListing 1.0

<210> 1

<211> 133

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 1

Glu Glu Glu Leu Gln Val Ile Gln Pro Asp Lys Ser Val Ser Val Ala

1 5 10 15

Ala Gly Glu Ser Ala Ile Leu His Cys Thr Val Thr Ser Leu Ile Pro

20 25 30

Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Ala Arg Glu Leu

35 40 45

Ile Tyr Asn Gln Lys Glu Gly His Phe Pro Arg Val Thr Thr Val Ser

50 55 60

Glu Ser Thr Lys Arg Glu Asn Met Asp Phe Ser Ile Ser Ile Ser Ala

65 70 75 80

Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Arg Lys

85 90 95

Gly Ser Pro Asp Thr Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu Ser

100 105 110

Val Arg Ala Lys Pro Ser Ala Pro Val Val Ser Gly Pro Ala Ala Arg

115 120 125

Ala Thr Pro Gln His

130

<210> 2

<211> 449

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 2

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr

20 25 30

Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile

35 40 45

Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys Phe

50 55 60

Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Asp Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys

85 90 95

Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Ser Gly

100 105 110

Thr Pro Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe

115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu

130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp

145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu

165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser

180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro

195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys

210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp

260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys

<210> 3

<211> 361

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 3

Glu Glu Glu Leu Gln Val Ile Gln Pro Asp Lys Ser Val Ser Val Ala

1 5 10 15

Ala Gly Glu Ser Ala Ile Leu His Cys Thr Val Thr Ser Leu Ile Pro

20 25 30

Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Ala Arg Glu Leu

35 40 45

Ile Tyr Asn Gln Lys Glu Gly His Phe Pro Arg Val Thr Thr Val Ser

50 55 60

Glu Ser Thr Lys Arg Glu Asn Met Asp Phe Ser Ile Ser Ile Ser Ala

65 70 75 80

Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Arg Lys

85 90 95

Gly Ser Pro Asp Thr Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu Ser

100 105 110

Val Arg Ala Lys Pro Ser Ala Pro Val Val Ser Gly Pro Ala Ala Arg

115 120 125

Ala Thr Pro Gln His Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser

145 150 155 160

Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser

165 170 175

Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys

180 185 190

Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg

195 200 205

Phe Ser Gly Ser Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser

210 215 220

Val Glu Ala Glu Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys

225 230 235 240

His Pro Leu Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Arg Thr

245 250 255

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu

260 265 270

Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro

275 280 285

Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly

290 295 300

Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr

305 310 315 320

Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His

325 330 335

Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val

340 345 350

Thr Lys Ser Phe Asn Arg Gly Glu Cys

355 360

<210> 4

<211> 597

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 4

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr

20 25 30

Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile

35 40 45

Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys Phe

50 55 60

Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Asp Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys

85 90 95

Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Ser Gly

100 105 110

Thr Pro Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe

115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu

130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp

145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu

165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser

180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro

195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys

210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro

225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp

260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val

290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys

325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

340 345 350

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr

355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu

385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys

405 410 415

Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu

420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly

435 440 445

Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

450 455 460

Glu Glu Glu Leu Gln Val Ile Gln Pro Asp Lys Ser Val Ser Val Ala

465 470 475 480

Ala Gly Glu Ser Ala Ile Leu His Cys Thr Val Thr Ser Leu Ile Pro

485 490 495

Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Ala Arg Glu Leu

500 505 510

Ile Tyr Asn Gln Lys Glu Gly His Phe Pro Arg Val Thr Thr Val Ser

515 520 525

Glu Ser Thr Lys Arg Glu Asn Met Asp Phe Ser Ile Ser Ile Ser Ala

530 535 540

Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Arg Lys

545 550 555 560

Gly Ser Pro Asp Thr Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu Ser

565 570 575

Val Arg Ala Lys Pro Ser Ala Pro Val Val Ser Gly Pro Ala Ala Arg

580 585 590

Ala Thr Pro Gln His

595

<210> 5

<211> 213

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 5

Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly

1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met

20 25 30

His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr

35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu

65 70 75 80

Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu Thr

85 90 95

Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro

100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr

115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys

130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu

145 150 155 160

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser

165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala

180 185 190

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe

195 200 205

Asn Arg Gly Glu Cys

210

<210> 6

<211> 597

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 6

Glu Glu Glu Leu Gln Val Ile Gln Pro Asp Lys Ser Val Ser Val Ala

1 5 10 15

Ala Gly Glu Ser Ala Ile Leu His Cys Thr Val Thr Ser Leu Ile Pro

20 25 30

Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Ala Arg Glu Leu

35 40 45

Ile Tyr Asn Gln Lys Glu Gly His Phe Pro Arg Val Thr Thr Val Ser

50 55 60

Glu Ser Thr Lys Arg Glu Asn Met Asp Phe Ser Ile Ser Ile Ser Ala

65 70 75 80

Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Arg Lys

85 90 95

Gly Ser Pro Asp Thr Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu Ser

100 105 110

Val Arg Ala Lys Pro Ser Ala Pro Val Val Ser Gly Pro Ala Ala Arg

115 120 125

Ala Thr Pro Gln His Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly

130 135 140

Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu

145 150 155 160

Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser

165 170 175

Phe Thr Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser

180 185 190

Leu Glu Trp Ile Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr

195 200 205

Asn Gln Lys Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser

210 215 220

Ser Thr Ala Tyr Met Asp Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala

225 230 235 240

Val Tyr Phe Cys Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr

245 250 255

Trp Gly Ser Gly Thr Pro Val Thr Val Ser Ser Ala Ser Thr Lys Gly

260 265 270

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly

275 280 285

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val

290 295 300

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe

305 310 315 320

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val

325 330 335

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val

340 345 350

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys

355 360 365

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu

370 375 380

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

385 390 395 400

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

405 410 415

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

420 425 430

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

435 440 445

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

450 455 460

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala

465 470 475 480

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

485 490 495

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

500 505 510

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

515 520 525

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

530 535 540

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

545 550 555 560

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

565 570 575

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

580 585 590

Leu Ser Pro Gly Lys

595

<210> 7

<211> 213

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 7

Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly

1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met

20 25 30

His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr

35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu

65 70 75 80

Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu Thr

85 90 95

Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro

100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr

115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys

130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu

145 150 155 160

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser

165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala

180 185 190

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe

195 200 205

Asn Arg Gly Glu Cys

210

<210> 8

<211> 330

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 8

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys

100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu

225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

325 330

<210> 9

<211> 15

<212> PRT

<213> 人工序列(Artificial Sequence)

<400> 9

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10 15

<210> 10

<211> 1347

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 10

caggtgcagc tgcagcagtc tggaccagag ctggagaagc ctggagcctc tgtgaagatc 60

tcctgtaagg cttctggcta ctccttcacc ggctatacaa tgaactgggt gaagcagagc 120

catggcaagt ctctggagtg gatcggcctg atcacccctt acaacggcgc ctccagctat 180

aatcagaagt ttaggggcaa ggctaccctg acagtggaca agtcttccag caccgcctat 240

atggacctgc tgagcctgac atctgaggat tccgccgtgt acttctgcgc taggggcgga 300

tatgacggaa ggggctttga ttactggggc tccggcaccc ctgtgacagt gtcttccgct 360

tccaccaagg gcccaagcgt gtttccactg gcccccagct ctaagagcac ctctggagga 420

acagccgctc tgggctgtct ggtgaaggat tacttcccag agcccgtgac agtgagctgg 480

aactctggcg ccctgacctc cggagtgcac acatttcccg ctgtgctgca gtccagcggc 540

ctgtatagcc tgtcttccgt ggtgaccgtg cctagctctt ccctgggcac ccagacatac 600

atctgcaacg tgaatcacaa gccctccaat acaaaggtgg acaagaaggt ggagcctaag 660

agctgtgata agacccatac atgcccccct tgtcctgctc cagagctgct gggcggacca 720

tccgtgttcc tgtttccacc caagcccaag gacaccctga tgatctccag aacccctgag 780

gtgacatgcg tggtggtgga cgtgtcccac gaggatccag aggtgaagtt caactggtac 840

gtggatggcg tggaggtgca taatgccaag accaagccaa gagaggagca gtacaattct 900

acctatcgcg tggtgtccgt gctgacagtg ctgcaccagg actggctgaa cggcaaggag 960

tacaagtgca aggtgagcaa taaggccctg cccgctccta tcgagaagac catctctaag 1020

gctaagggcc agcccaggga gccacaggtg tacaccctgc ctccaagccg ggacgagctg 1080

accaagaacc aggtgtctct gacatgtctg gtgaagggct tctacccatc tgacatcgcc 1140

gtggagtggg agtccaatgg ccagcccgag aacaattata agaccacacc ccctgtgctg 1200

gactccgatg gcagcttctt tctgtactcc aagctgaccg tggataagag ccgctggcag 1260

cagggcaacg tgttttcctg tagcgtgatg catgaggctc tgcacaatca ttacacacag 1320

aagtctctgt ccctgagccc cggcaag 1347

<210> 11

<211> 399

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 11

gaggaggagc tgcaggtcat ccagccagac aagtccgtga gcgtggctgc tggagagagc 60

gccatcctgc attgtaccgt gacatctctg atcccagtgg gaccaatcca gtggtttagg 120

ggagctggac ctgctcggga gctgatctac aaccagaagg agggccactt cccaagagtg 180

accacagtgt ctgagtccac caagcgcgag aatatggact ttagcatctc tatctccgct 240

atcaccccag ccgatgctgg cacatactat tgcgtgaagt tcagaaaggg ctcccccgat 300

accgagttta agagcggagc tggaacagag ctgtctgtga gggccaagcc ttctgctcca 360

gtggtgtccg gccccgccgc tcgggctacc cctcagcac 399

<210> 12

<211> 639

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 12

gacatcgagc tgacccagag cccagctatc atgtccgcct ccccaggaga gaaggtgacc 60

atgacatgtt ccgcctcctc ctccgtgtcc tacatgcatt ggtatcagca gaagtctggc 120

acctccccca agagatggat ctacgataca agcaagctgg cttctggagt gcctggccgc 180

ttctccggaa gcggatctgg caactcctat agcctgacca tctccagcgt ggaggccgag 240

gacgatgcta catactattg ccagcagtgg tctaagcatc ctctgacctt tggctccggc 300

acaaaggtgg agatcaagag gaccgtggcc gctccatccg tgttcatctt tccccctagc 360

gacgagcagc tgaagtccgg cacagccagc gtggtgtgcc tgctgaacaa tttctacccc 420

cgggaggcca aggtgcagtg gaaggtggat aacgctctgc agagcggcaa ttctcaggag 480

tccgtgaccg agcaggacag caaggattct acatattccc tgtcttccac cctgacactg 540

tctaaggccg actacgagaa gcacaaggtg tatgcttgcg aggtgaccca tcagggcctg 600

agctctcctg tgacaaagtc ctttaatcgc ggcgagtgt 639

<210> 13

<211> 1083

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 13

gaggaggagc tgcaggtcat ccagccagac aagtccgtga gcgtggctgc tggagagagc 60

gccatcctgc attgtaccgt gacatctctg atcccagtgg gaccaatcca gtggtttagg 120

ggagctggac ctgctcggga gctgatctac aaccagaagg agggccactt cccaagagtg 180

accacagtgt ctgagtccac caagcgcgag aatatggact ttagcatctc tatctccgct 240

atcaccccag ccgatgctgg cacatactat tgcgtgaagt tcagaaaggg ctcccccgat 300

accgagttta agagcggagc tggaacagag ctgtctgtga gggccaagcc ttctgctcca 360

gtggtgtccg gccccgccgc tcgggctacc cctcagcacg gaggaggagg aagcggcgga 420

ggaggctctg gcggcggcgg ctccgacatc gagctgaccc agagcccagc tatcatgtcc 480

gcctccccag gagagaaggt gaccatgaca tgttccgcct cctcctccgt gtcctacatg 540

cattggtatc agcagaagtc tggcacctcc cccaagagat ggatctacga tacaagcaag 600

ctggcttctg gagtgcctgg ccgcttctcc ggaagcggat ctggcaactc ctatagcctg 660

accatctcca gcgtggaggc cgaggacgat gctacatact attgccagca gtggtctaag 720

catcctctga cctttggctc cggcacaaag gtggagatca agaggaccgt ggccgctcca 780

tccgtgttca tctttccccc tagcgacgag cagctgaagt ccggcacagc cagcgtggtg 840

tgcctgctga acaatttcta cccccgggag gccaaggtgc agtggaaggt ggataacgct 900

ctgcagagcg gcaattctca ggagtccgtg accgagcagg acagcaagga ttctacatat 960

tccctgtctt ccaccctgac actgtctaag gccgactacg agaagcacaa ggtgtatgct 1020

tgcgaggtga cccatcaggg cctgagctct cctgtgacaa agtcctttaa tcgcggcgag 1080

tgt 1083

<210> 14

<211> 1791

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 14

caggtgcagc tgcagcagtc tggacctgag ctggagaagc caggagcctc cgtgaagatc 60

agctgtaagg cttccggcta cagcttcacc ggctatacaa tgaactgggt gaagcagtct 120

catggcaagt ccctggagtg gatcggcctg atcaccccat acaacggcgc ctccagctat 180

aatcagaagt ttagaggcaa ggctaccctg acagtggaca agtcttccag caccgcctat 240

atggacctgc tgtctctgac atccgaggat agcgccgtgt acttctgcgc taggggcgga 300

tatgacggaa ggggctttga ttactggggc tctggaaccc ctgtgaccgt gtcctccgcc 360

tccaccaagg gaccatccgt gttcccactg gcccccagct ctaagagcac ctctggagga 420

acagccgctc tgggctgtct ggtgaaggat tacttcccag agcccgtgac agtgtcttgg 480

aactccggcg ccctgacctc tggagtgcac acatttcctg ctgtgctgca gtccagcggc 540

ctgtattccc tgtcttccgt ggtgaccgtg ccaagctctt ccctgggcac ccagacatac 600

atctgcaacg tgaatcacaa gccctctaat acaaaggtgg acaagaaggt ggagcctaag 660

tcctgtgata agacccatac atgcccccct tgtcctgctc cagagctgct gggcggacca 720

agcgtgttcc tgtttccacc caagcccaag gacaccctga tgatcagccg cacccctgag 780

gtgacatgcg tggtggtgga cgtgtctcac gaggatccag aggtgaagtt caactggtac 840

gtggatggcg tggaggtgca taatgccaag accaagccca gggaggagca gtacaattct 900

acctatcggg tggtgtccgt gctgacagtg ctgcaccagg actggctgaa cggcaaggag 960

tacaagtgca aggtgtccaa taaggccctg cccgctccta tcgagaagac catcagcaag 1020

gctaagggcc agcccaggga gccacaggtg tacaccctgc ctccatcccg ggacgagctg 1080

accaagaacc aggtgagcct gacatgtctg gtgaagggct tctacccatc tgacatcgcc 1140

gtggagtggg agtccaatgg ccagcccgag aacaattata agaccacacc ccctgtgctg 1200

gacagcgatg gctctttctt tctgtactcc aagctgaccg tggacaagag caggtggcag 1260

cagggcaacg tgttttcctg cagcgtgatg catgaggctc tgcacaatca ttatacacag 1320

aagtctctgt ccctgagccc cggcaaggga ggaggaggat ccggaggagg aggaagcggc 1380

ggcggcggct ctgaggagga gctgcaggtc atccagcctg ataagtccgt gtccgtggct 1440

gctggagaga gcgccatcct gcactgtacc gtgacatctc tgatccccgt gggccctatc 1500

cagtggttta gaggagctgg accagctcgc gagctgatct acaaccagaa ggagggccat 1560

ttccctagag tgaccacagt gagcgagtct accaagcgcg agaatatgga cttttccatc 1620

agcatctctg ccatcacccc agccgatgct ggcacatact attgcgtgaa gttccggaag 1680

ggctctcccg ataccgagtt taagtccggc gctggcacag agctgagcgt gagagccaag 1740

ccatccgctc ccgtggtgag cggccccgcc gctcgcgcca cccctcagca t 1791

<210> 15

<211> 639

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 15

gacatcgagc tgacccagag cccagctatc atgtccgcct ccccaggaga gaaggtgacc 60

atgacatgtt ccgcctcctc ctccgtgtcc tacatgcatt ggtatcagca gaagagcggc 120

acctctccta agaggtggat ctacgataca tccaagctgg cctccggagt gccaggccgg 180

ttctctggat ccggaagcgg caactcttat tccctgacca tctccagcgt ggaggccgag 240

gacgatgcta catactattg ccagcagtgg agcaagcacc ccctgacctt tggctctggc 300

acaaaggtgg agatcaagag aaccgtggcc gctccttccg tgttcatctt tcccccttcc 360

gacgagcagc tgaagtctgg cacagcctcc gtggtgtgcc tgctgaacaa tttctaccca 420

cgcgaggcca aggtgcagtg gaaggtggat aacgctctgc agtccggcaa tagccaggag 480

tctgtgaccg agcaggactc caaggatagc acatattctc tgtcttccac cctgacactg 540

tccaaggccg actacgagaa gcacaaggtg tatgcttgcg aggtgaccca tcagggcctg 600

agctctcccg tgacaaagag ctttaatagg ggcgagtgt 639

<210> 16

<211> 1791

<212> DNA

<213> 人工序列(Artificial Sequence)

<400> 16

gaggaggagc tgcaggtcat ccagccagac aagagcgtgt ctgtggccgc tggcgagtct 60

gctatcctgc attgtaccgt gacatccctg atcccagtgg gaccaatcca gtggtttagg 120

ggagctggac ctgctaggga gctgatctat aaccagaagg agggccactt cccaagagtg 180

accacagtgt ccgagagcac caagcgcgag aatatggact tttctatctc catcagcgcc 240

atcaccccag ccgatgctgg cacatactat tgcgtgaagt tcaggaaggg cagccccgat 300

accgagttta agtctggcgc tggcacagag ctgtccgtga gagccaagcc ttccgcccca 360

gtggtgtctg gccccgccgc tcgcgccacc cctcagcatg gaggaggagg atccggagga 420

ggaggcagcg gcggcggcgg ctctcaggtg cagctgcagc agagcggacc tgagctggag 480

aagccaggag cctccgtgaa gatcagctgt aaggcttccg gctacagctt caccggctat 540

acaatgaact gggtgaagca gtctcatggc aagtccctgg agtggatcgg cctgatcacc 600

ccttacaacg gcgcctccag ctataatcag aagtttcggg gcaaggctac cctgacagtg 660

gacaagtctt ccagcaccgc ctatatggac ctgctgtctc tgacatccga ggatagcgcc 720

gtgtacttct gcgctagagg aggatatgac ggaaggggct ttgattactg gggctctggc 780

acccctgtga cagtgtcttc cgcttccacc aagggaccaa gcgtgttccc actggctcct 840

agctctaagt ctacctccgg aggaacagcc gctctgggct gtctggtgaa ggattacttc 900

ccagagcccg tgacagtgtc ttggaactcc ggcgccctga cctctggagt gcatacattt 960

cctgctgtgc tgcagtccag cggcctgtat tccctgtctt ccgtggtgac cgtgccaagc 1020

tcttccctgg gcacccagac atacatctgc aacgtgaatc acaagccctc caatacaaag 1080

gtggacaaga aggtggagcc taagagctgt gataagaccc atacatgccc cccttgtcct 1140

gctccagagc tgctgggcgg accaagcgtg ttcctgtttc cacccaagcc caaggacacc 1200

ctgatgatct ccagaacccc cgaggtgaca tgcgtggtgg tggacgtgtc ccacgaggat 1260

cctgaggtga agtttaactg gtacgtggat ggcgtggagg tgcataatgc caagaccaag 1320

cccagggagg agcagtacaa ttctacctat cgggtggtgt ccgtgctgac agtgctgcac 1380

caggactggc tgaacggcaa ggagtacaag tgcaaggtga gcaataaggc cctgcccgct 1440

cctatcgaga agaccatctc taaggctaag ggccagccaa gggagcccca ggtgtacacc 1500

ctgcctccaa gccgggacga gctgaccaag aaccaggtgt ctctgacatg tctggtgaag 1560

ggcttctacc catccgacat cgccgtggag tgggagagca atggccagcc cgagaacaat 1620

tataagacca caccccctgt gctggacagc gatggctctt tctttctgta cagcaagctg 1680

accgtggata agtctcgctg gcagcagggc aacgtgttta gctgttctgt gatgcatgag 1740

gccctgcaca atcattacac acagaagtcc ctgagcctgt ctcctggcaa g 1791

相关技术
  • 一种重组双功能融合蛋白及应用
  • 一种新的重组双功能融合蛋白及其制备和应用
技术分类

06120112612437